{"id":3867,"date":"2018-12-27T11:59:39","date_gmt":"2018-12-27T06:29:39","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=3867"},"modified":"2021-07-24T12:57:09","modified_gmt":"2021-07-24T07:27:09","slug":"the-business-cocktail-49","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-49","title":{"rendered":"Vedanta raises; Relay Therapeutics reels in; Gene therapy for SMA"},"content":{"rendered":"\n<p><strong>Vedanta raises USD 27 Million to move microbiome assets through the clinic<\/strong><\/p>\n\n\n\n<p class=\"has-background has-very-light-gray-background-color\"><strong>Vedanta Biosciences<\/strong>&nbsp;raises <strong>USD 27 million<\/strong> in its <strong>series C round<\/strong>. The cash will bolster its microbiome-derived drugs pipeline.&nbsp;The capital will aid a <strong>phase 1\/2 trial of VE416<\/strong> in food <a href=\"https:\/\/www.delveinsight.com\/report-store\/peanut-allergy-market\">allergy<\/a>, a <strong>phase 2 study<\/strong> of VE303 in recurrent C. difficile infection and a <strong>phase 1b\/2 study of VE800<\/strong> in combination with <strong>Bristol-Myers Squibb<\/strong>\u2019s Opdivo in advanced or metastatic cancers. The funding comes from the <strong>Bill &amp; Melinda Gates Foundation, Bristol-Myers Squibb, Rock Springs Capital, Invesco Asset Management, Seventure Partners, and PureTech Health<\/strong>.&nbsp;<\/p>\n\n\n\n<p><strong>Relay\nTherapeutics reels in USD 400 Million to accelerate discovery <\/strong><\/p>\n\n\n\n<p class=\"has-background has-very-light-gray-background-color\"><strong>Relay Therapeutics<\/strong> is bagged a massive USD 400 million series C round to ramp up its platform technology and discovery efforts, build its pipeline and push itself into the clinic.&nbsp;Before&nbsp;launching&nbsp;out of Third Rock Ventures with a <strong>USD 57 million<\/strong> series A, the company worked silently for about a year, mission is to create new treatments against targets that were previously considered undruggable, with an initial focus on cancer.&nbsp;Relay is looking to modulate these changes to create next-generation treatments for cancer.<\/p>\n\n\n\n<p><strong>Gene\ntherapy could be cost effective in <\/strong><strong>spinal muscular atrophy (SMA)<\/strong><\/p>\n\n\n\n<p class=\"has-background has-very-light-gray-background-color\"><strong>Biogen\u2019s Spinraza<\/strong> was approved by the <strong>FDA<\/strong> as the first and only disease-modifying treatment for SMA, a rare and often fatal genetic muscular disorder. The price tag is&nbsp;USD 750,000 for the first year of therapy. Though high, a report by the&nbsp;Institute for Clinical and Economic Review (<strong>ICER<\/strong>) has suggested&nbsp;Zolgensma, <strong>Novartis<\/strong>\u2019 experimental SMA gene therapy. It could be more cost-effective in the long run versus Spinraza. <strong>Zolgensma <\/strong>is currently under FDA review.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Vedanta raises USD 27 Million to move microbiome assets through the clinic Vedanta Biosciences&nbsp;raises USD 27 million in its series C round. The cash will bolster its microbiome-derived drugs pipeline.&nbsp;The capital will aid a phase 1\/2 trial of VE416 in food allergy, a phase 2 study of VE303 in recurrent C. difficile infection and a [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":3693,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[830,258,2355,2357,2249],"industry":[17225],"therapeutic_areas":[17235,17245,17278,17234],"class_list":["post-3867","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-biogen","tag-gene-therapy","tag-relay-therapeutics","tag-spinraza","tag-vedanta-biosciences","industry-pharmaceutical","therapeutic_areas-cell-and-gene-therapy","therapeutic_areas-neurology","therapeutic_areas-other-diseases","therapeutic_areas-rare-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Vedanta bags $27M; Relay raises $400M; Gene therapy for SMA<\/title>\n<meta name=\"description\" content=\"Vedanta Biosciences raises USD 27 million in its series C round. The cash will bolster its microbiome-derived drugs pipeline. The capital will aid...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-49\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Vedanta bags $27M; Relay raises $400M; Gene therapy for SMA\" \/>\n<meta property=\"og:description\" content=\"Vedanta Biosciences raises USD 27 million in its series C round. The cash will bolster its microbiome-derived drugs pipeline. The capital will aid...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-49\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2018-12-27T06:29:39+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:27:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/11\/09020519\/HCGHR-2.2-Image1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"3000\" \/>\n\t<meta property=\"og:image:height\" content=\"1992\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Vedanta bags $27M; Relay raises $400M; Gene therapy for SMA","description":"Vedanta Biosciences raises USD 27 million in its series C round. The cash will bolster its microbiome-derived drugs pipeline. The capital will aid...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-49","og_locale":"en_US","og_type":"article","og_title":"Vedanta bags $27M; Relay raises $400M; Gene therapy for SMA","og_description":"Vedanta Biosciences raises USD 27 million in its series C round. The cash will bolster its microbiome-derived drugs pipeline. The capital will aid...","og_url":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-49","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2018-12-27T06:29:39+00:00","article_modified_time":"2021-07-24T07:27:09+00:00","og_image":[{"width":3000,"height":1992,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/11\/09020519\/HCGHR-2.2-Image1.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-49","url":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-49","name":"Vedanta bags $27M; Relay raises $400M; Gene therapy for SMA","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-49#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-49#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/11\/09020519\/HCGHR-2.2-Image1.jpg","datePublished":"2018-12-27T06:29:39+00:00","dateModified":"2021-07-24T07:27:09+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Vedanta Biosciences raises USD 27 million in its series C round. The cash will bolster its microbiome-derived drugs pipeline. The capital will aid...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-49"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-49#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/11\/09020519\/HCGHR-2.2-Image1.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/11\/09020519\/HCGHR-2.2-Image1.jpg","width":"3000","height":"1992","caption":"vedanta"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/11\/09020519\/HCGHR-2.2-Image1-300x199.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Biogen<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Gene therapy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Relay Therapeutics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Spinraza<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Vedanta Biosciences<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Biogen<\/span>","<span class=\"advgb-post-tax-term\">Gene therapy<\/span>","<span class=\"advgb-post-tax-term\">Relay Therapeutics<\/span>","<span class=\"advgb-post-tax-term\">Spinraza<\/span>","<span class=\"advgb-post-tax-term\">Vedanta Biosciences<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 7 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Dec 27, 2018","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Dec 27, 2018 11:59 am","modified":"Updated on Jul 24, 2021 12:57 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/3867","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=3867"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/3867\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/3693"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=3867"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=3867"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=3867"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=3867"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=3867"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}